Nagata Y, et al. - Experts analyzed how anti-tumor necrosis factor (TNF) therapy impacts the initial intestinal surgery for Crohn’s disease (CD) in this single-center retrospective cohort study. For this investigation, they reviewed the clinical course of 199 inflammatory-type CD patients at the initial diagnosis (the period between 1973 and 2014) until the end of 2016. Among patients with inflammatory-type CD at initial diagnosis, anti-TNF therapy can lower the risk for intestinal surgery. They observed that immunomodulators did not seem to reduce the risk of initial intestinal surgery.